X-linked Hypophosphatemia

X-linked hypophosphatemia (XLH) is the most common hereditary form of rickets and a multisystem disorder that requires treatment by multidisciplinary teams.
Data from gait analysis combined with clinical and radiological data showed a significant reduction in gait quality, ankle power, and plantar flexion.63–65 The authors attributed these findings to the presence of structural changes such as subtalar osteoarthritis, femoral maltorsion, and tibiofemoral angular deformities, with varus deformity having a greater impact on gait than valgus deformity.

Burosumab is a relatively new human monoclonal antibody treatment for XLH patients. It has been shown to improve renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, physical function, and reduce pain and the severity of rickets.